HKUMed unveils innovative clinical tool and investigates telemedicine for post-stroke hypertension management

HKUMed successfully conducts the first CAR-T cell therapy in Hong Kong for end-stage multiple myeloma using an advanced cellular product from the mainland

FDA and EMA designations for HKUMed game-changing invention: Oral arsenic trioxide for leukaemia with a 97% cure rate
First prescription medicine in Hong Kong to be globalised

HKUMed study finds 80% mislabelled NSAID allergies among stroke patients leads to poorer treatment outcomes and urges evaluation to identify mislabelling

HKUMed research finds high blood glucose weakens immunity against viral infections in type 2 diabetes patients

HKUMed forecasts an ongoing depression burden through 2032 Annual average cost of care expected to be over HK$2.5 billion

HKUMed territory-wide studies reveal the benefits of optimal diabetes control in reducing the risk of colorectal and liver cancer by 30%

HKUMed finds critically ill influenza patients face double the risk of acute kidney injury than COVID-19 patients

HKUMed develops medical-grade smartphone stethoscope to support valvular heart disease detection

HKUMed finds biosimilars offer improved outcome and lower cost for rheumatoid arthritis treatment

HKU Medical Professor Xu Aimin receives State Natural Science Award (Second Class Prize)

HKUMed study finds good clinical outcomes for over 30% of ischaemic stroke patients receiving endovascular treatment beyond six hours from onset

HKUMed achieves global breakthrough in personalised stem cell treatment for immunodeficiency patients, urges awareness and advocacy

HKUMed and the Correctional Services Department launch a pilot programme for hepatitis C virus screening and treatment for eligible persons in custody on a voluntary basis

HKUMed identifies PLK4 as a promising therapeutic target for TP53 mutated AML, demonstrated in Queen Mary Hospital and other studies

HKUMed validates a novel technique that identifies coronary artery disease patients who should undergo PCI

HKUMed joins Lancet Commission to call for international collaboration and multidisciplinary action to reduce sudden cardiac deaths

HKUMed finds global prevalence of H. pylori infection steadily declining over 40 years - Combination of antibiotics in treating H. pylori could alter the virus community in the gut

心臟病治療發展 (播出時間：2月21日(星期二) 晚上8時 | 港台電視31)
主持：鄧智偉教授
嘉實：謝鴻發教授（香港大學內科學系講座教授）

吸煙以外肺癌風險因素逐個捉
港大林志良醫生:遠離空氣污染小貼士

香港開電視《Fit開有條路》
喬夏利醫生：血癌

HKU medical research team starts large-scale clinical trial on COVID-19 Vaccine (Omicron Variant)

香港開電視《Fit開有條路》
鄧智偉教授：慢性腎病

A collaboration study led by HKUMed finds that patients with treatment-resistant depression (TRD) have greater risk of mortality and healthcare costs; calls for early and subsequent clinical monitoring

HKUMed researchers identified a key molecule in extracellular vesicles of liver cancer patient as a potential new biomarker for early diagnosis and therapeutic target

香港電台《醫生與你》
林志良醫生：慢性阻塞性肺病1

香港電台《醫生與你》
【醫學．人】楊紫芝 (下)

香港電台《醫生與你》
【醫學．人】楊紫芝 (上)

香港開電視《Fit開有條路》
趙頴欣醫生：關注乳癌

香港開電視《Fit開有條路》
謝偉財教授：淋巴瘤

有線電視《聽吓醫生講》 
謝偉財教授：常流夜汗要注意！從4大症狀看出淋巴瘤

有線電視《聽吓醫生講》 
謝偉財教授：人體血液冷知識 濃縮凝血因子助血友病患者

香港開電視《Fit開有條路》
蕭頌華教授：心律不正與遙距監察

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

有線電視《聽吓醫生講》
司徒偉基教授：多功能醫生育成大法

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

有線電視《聽吓醫生講》
司徒偉基教授：乙肝知多D

有線電視《聽吓醫生講》
孔繁毅教授：「接種疫苗好重要！」